View ValuationPressure BioSciences 将来の成長Future 基準チェック /06現在、 Pressure BioSciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長17.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Dec 23Pressure Biosciences Provides Revenue Guidance for Fourth Quarter 2022 and First Quarter 2023Pressure BioSciences provided revenue Guidance for fourth quarter 2022 and First quarter 2023. Company offered guidance that its Fourth Quarter 2022 revenue will exceed quarterly revenue for any quarter over the past four years, and may achieve the highest quarterly revenue ever for the Company. The Company further believes First Quarter 2023 revenue will greatly exceed Fourth Quarter 2022's expected strong results, and that revenues in each successive quarter will surpass the prior quarter's level. Management expects the Company to reach breakeven/profitability by the end of 2023.すべての更新を表示Recent updatesお知らせ • May 18Pressure BioSciences, Inc. announced delayed 10-Q filingOn 05/17/2024, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Pressure BioSciences, Inc. announced delayed annual 10-K filingOn 04/01/2024, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 23Pressure BioSciences, Inc. (OTCPK:PBIO) completed the acquisition of CBH International LLC.Pressure BioSciences, Inc. (OTCPK:PBIO) entered into a definitive agreement to acquire CBH International LLC on January 11, 2024. Under the terms of the agreement, Uncle Bud's stockholders will be entitled to receive preferred stock of PBIO that is convertible into shares of PBIO common stock and no cash at the closing of the transaction. In addition, the parties agreed to an earnout for additional shares of PBIO common stock based on the achievement of revenue and net profit results in 2024. Such shares will be subject to standard restrictions on resale. Upon the closing of the transaction, the combined company intends to become a leading provider of topicals and other consumer products, leveraging PBIO’s UltraShear technology platform for nanoemulsified products that deliver industry-leading speed of action and bioavailability. All employees of CBH International became employees of Pressure BioSciences and CBH International became the Consumer Products Business Unit of Pressure BioSciences. The transaction has been unanimously approved by the Boards of Directors of both companies and is subject to customary closing conditions. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close by January 19, 2024.Pressure BioSciences, Inc. (OTCPK:PBIO) completed the acquisition of CBH International LLC on January 22, 2024.お知らせ • Dec 13Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food SafetyPressure BioSciences, Inc. announced the publication of a pivotal scientific study in the critical field of food safety, featuring the Company's Ultra Shear TechnologyTM (UltraShearTM orUSTTM) platform. The recently published article, entitled "Synergistic Effects of Pressure, Temperature, Shear, and Their interactions on Clostridium sporogenes PA3679 Spore Inactivation During Ultra-Shear Processing" was featured in the peer-reviewed journal "Innovative Food Science and Emerging Technologies." This collaborative effort involved esteemed academic scientists from The Ohio State University ("Ohio State") College of Food, agricultural, and Environmental Sciences ("CFAES"), with co-authorship by PBIO's Senior Vice President of Engineering, Dr. Edmund Y. Ting. The publication underscores the efficacy of PBI's revolutionary USTTM platform in advancing food safety, preservation, stability, and enhancing consumer sensory experiences. The collaborative effort between The Ohio State University and PBIO has successfully developed conditions that leverage the positive effects of high-pressure homogenization, controlled exposure to elevated temperatures, and high hydrostatic pressure within the UltraShear equipment, resulting in a significant reduction of viable bacterial spores while maintaining high product quality compared to current food processing methods such as thermal inactivation. Key Highlights from the Publication: The article demonstrates the potential of UltraShear inactivation of foodborne bacterial spores by uniquely combining controlled temperature, pressure, and high fluid shear; The publication signals the future possibility of UltraShear processing of shelf-stable low-acid fluid products to maximize nutritional and sensory qualities for heat-sensitive products while significantly decreasing the potential of bacterial contamination, including spores; The authors validated the compatibility of conventional clean-in-place protocols with the UltraShear equipment.お知らせ • Dec 02Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST AmbassadorPressure BioSciences, Inc. announced that VST has launched public availability of their first collaboration product, a Nano CBD Topical Spray with revolutionary fast performance enabled by PBIO's unique, patented UltraShear™ nanoemulsions platform technology. Marketed by VST, the product is named "Valor CBD" inspired by the courage of Nation's true heroes, the men and women who have selflessly served country. PBIO's UltraShear™ Technology (UltraShearTM or USTTM) platform allows oil-soluble active molecules (like CBD) to be prepared into nanoemulsions of vanishingly tiny oil droplets in water. The precisely controlled resulting nano-emulsion ensures breakthrough speed of absorption and unparalleled circulating availability of the active oil-soluble ingredients (CBD or other active molecules) to the water-based biochemistry of bodies (human or animals). "Quite simply, conventional oil and cream products have a low rate of absorption, so the products do not work quickly or effectively. Products made with UltraShear platform change that equation completely, producing nanoemulsions of CBD oil in water ("Nano CBD"), that deliver unprecedented speed of topical action, unparalleled bioavailability, and reliably dosed payload delivery," commented John B. Hollister, PBIO's Director of Marketing and Sales. Mr. Hollister added that PBIO is now capable of commercially processing Nano CBD in the Company's west coast partner's manufacturing facilities. This past summer, PBIO announced a five-year strategic partnership with VST, focused on benefiting the broad active duty and veteran's communities. Howard Zall, COO of VST, stated that VST had independently determined that PBIO's Ultra Shear Technology was the world's leading platform for creating the most highly effective nanoemulsions of CBD in either topical or oral spray formats.お知らせ • Nov 17Pressure BioSciences, Inc. announced delayed 10-Q filingOn 11/15/2023, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17Pressure BioSciences, Inc. announced delayed 10-Q filingOn 08/15/2023, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 18Pressure BioSciences, Inc. Announces UltraShear Nano-CBD Roll-Out Program Enters Rapid Expansion Phase of Distribution and PartneringPressure BioSciences, Inc. announced in an interview with renowned cannabis business authority Jeffrey Friedland that PBIO was now advancing into Phase 2 of commercialization of its revolutionarily-effective, UltraShear™-processed nanoemulsified CBD topical spray, transitioning from early, targeted sales and marketing efforts into rapid expansion plans for its nationwide and global distribution base. PBIO's President and CEO, Mr. Richard T. Schumacher explained in the interview: There has been significant noise in the CBD and broader cannabis markets from companies touting a nanoemulsion offering in the past few years, but none are able to match UltraShear's capability to deliver tightly controlled nano-droplet sizes in the sub-100 nm range, with rock-solid stability, easily and affordable scaled-up production efficiency, and elimination of the metal contamination resulting from the most commonly-used competitive technology. The company initially hand-picked a small, select group of retailers for its first round of efforts in the sale and distribution of the company’s Nano-CBD Topical Spray product, which allowed the company to explore and optimize factors like product formulation, CBD concentration targets, bottle and dispenser technology, product size and packaging configuration, pricing, and shipping logistics. This first phase of activity was extremely productive in answering those questions. The company now have a confidently-designed product and an accumulation of powerful UltraShear Nano-CBD Topical Spray user testimonials. Mr. Schumacher continued: Effective this week, the company enter PBIO's Phase 2 of the company's Nano-CBD commercialization strategy with rapidly expanding efforts to welcome and integrate many additional retailers and wholesalers across the USA, while the company introduce and establish it uniquely fast-acting and potent Nano-CBD topical spray to the broader U.S. and global markets. As the company had mentioned in recent news releases, independent research by a leading cannabis academic team has dramatically confirmed its UltraShear-processed Nano-CBD product to have uniquely differentiated performance over all existing known CBD products (compared to the gold standard of IV infusion), and the company anticipate the release of those results in a peer-reviewed scientific journal in the near future. Pressed by Mr. Friedman to discuss the expected impact of this announced Phase 2 upon PBIO's business results for the remainder of 2023 and beyond, Mr. Schumacher concluded: the company anticipate signing up over 20 retailers and wholesalers in the remainder of 2023, with an estimated incremental revenue impact of $2 million to $3 million over 2022 results. The company also plan to launch its UltraShear Nano-CBD OralSpray product this October 2023. Over the next 12 months, the company’s goal is to sign and launch at least 50 new UltraShear Nano-CBD retailers and wholesalers, and to achieve at least $10 million in incremental revenue impact in 2024.お知らせ • Jun 28Pressure Biosciences, Inc. Announces Results from Third Round of Consumer Focus Group Testing of THC Nanoemulsion Oral SprayPressure BioSciences, Inc. announced results from a third round of consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks and under the tongue. The Nano-THC Oral Spray was prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products. An additional 25 consumers recently participated in this on-going focus group testing, bringing the total to over 60 participants to date. Once again, the respondents strongly affirmed key attributes that powerfully differentiate UltraShear processed Nano-THC Oral Spray from the participants previous edible THC experiences, with major emphasis on: Speedy onset of first effects (average well under ten minutes, with many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes for initial onset. Much faster progression to maximum effects (average well under 30 minutes, with many reports in 20 minutes or less) versus typical THC edibles requiring 60-120 minutes. Elimination of health issues associated with smoking or vaping. Efficiency improvements in dose payload delivery, with many reporting equal or better/greater THC experience from dosing at a fraction of user's normal dosing levels. Stable, all plant formulation is sterile packaged with no added preservatives. Multiple consumers applied a single spray to painful body areas and reported fast to instant transdermal pain relief. Multiple consumers with difficulty in falling asleep detailed how they quickly fell asleep and remained asleep through the night.お知らせ • Jan 20Pressure Biosciences, Inc. Announces Results from Initial Consumer Focus Group Testing of A THC Nanoemulsion Oral Spray Prepared Using PBI's Revolutionary Ultra Shear TechnologyPressure BioSciences, Inc. announced results from initial consumer focus group testing of a THC Nanoemulsion Oral Spray prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™ or UST™) platform. Preparation of the THC Nanoemulsion Oral Spray was completed by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products in CA.お知らせ • Dec 23Pressure Biosciences Provides Revenue Guidance for Fourth Quarter 2022 and First Quarter 2023Pressure BioSciences provided revenue Guidance for fourth quarter 2022 and First quarter 2023. Company offered guidance that its Fourth Quarter 2022 revenue will exceed quarterly revenue for any quarter over the past four years, and may achieve the highest quarterly revenue ever for the Company. The Company further believes First Quarter 2023 revenue will greatly exceed Fourth Quarter 2022's expected strong results, and that revenues in each successive quarter will surpass the prior quarter's level. Management expects the Company to reach breakeven/profitability by the end of 2023.お知らせ • Dec 08+ 1 more updatePressure BioSciences, Inc., Annual General Meeting, Dec 29, 2022Pressure BioSciences, Inc., Annual General Meeting, Dec 29, 2022, at 11:00 US Eastern Standard Time.お知らせ • Nov 16Pressure BioSciences, Inc. announced delayed 10-Q filingOn 11/15/2022, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 04Emergent Health Corp (OTCPK:EMGE) completed the acquisition of Pressure BioSciences, Inc. (OTCPK:PBIO).Emergent Health Corp (OTCPK:EMGE) executed a Letter of Intent to acquire Pressure BioSciences, Inc. (OTCPK:PBIO) on July 6, 2022. On July 19, 2022, Regen's Bankruptcy Motion to Dismiss was approved by the US Bankruptcy Court in New Jersey. The transaction is anticipated to close from mid-to-end July 2022. The transaction is expected to close on or about August 1, 2022. Emergent Health Corp (OTCPK:EMGE) completed the acquisition of Pressure BioSciences, Inc. (OTCPK:PBIO) on August 2, 2022. As per the terms of the transaction, acquisition was made for preferred stock of Emergent and other financial considerations. Jim Morrison, President and Chief Executive Officer of Regen has joined the Emergent Board of Directors.お知らせ • Jul 07Emergent Health Corp (OTCPK:EMGE) executed a Letter of Intent to acquire Pressure BioSciences, Inc. (OTCPK:PBIO)Emergent Health Corp (OTCPK:EMGE) executed a Letter of Intent to acquire Pressure BioSciences, Inc. (OTCPK:PBIO) on July 6, 2022. The transaction is anticipated to close from mid-to-end July 2022.お知らせ • May 18Pressure BioSciences, Inc. announced delayed 10-Q filingOn 05/17/2022, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Pressure BioSciences, Inc. announced delayed annual 10-K filingOn 04/01/2022, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 18Pressure BioSciences, Inc. announced delayed 10-Q filingOn 08/17/2021, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Pressure BioSciences, Inc. announced delayed annual 10-K filingOn 04/01/2021, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 25Pressure BioSciences and The Ohio State University Announce Food Industry Consortium to Advance Commercialization of PBI's Ultra Shear TechnologyPressure BioSciences, Inc. announced it has entered into a wide-ranging agreement with the College of Food, Agricultural, and Environmental Sciences at The Ohio State University ("Ohio State"). Under the Agreement, bench-top and floor model test systems of PBI's patented Ultra Shear Technology™ platform for the high shear processing of liquids under controlled temperature and pressure conditions will be set up in the acclaimed Ohio State food pilot plant. To help introduce the potential of the UST platform for strategic innovation to global food companies, PBI and Ohio State have announced the formation of a food industry consortium (the "Consortium"), whose members will have access to the UST test systems in the pilot plant, as well as licensing rights to the UST platform. The Consortium is the result of research initially sponsored by the USDA NIFA for which Ohio State and PBI gratefully acknowledge their support. The primary goals of the Consortium are to develop and improve new commercial applications of UST; help develop the scientific support needed to address possible regulatory issues; and to experience first-hand UST product development and pre-commercialization efforts. The Consortium will be open to food companies worldwide. Consortium members will help direct the scientific efforts of Ohio State and PBI across a universe of prospective liquid food & beverage projects. Topics of interest will include spore inactivation and other pathogen and spoilage factor control; enhanced taste, smell, and other sensory qualities; and the formation of highly stable products suitable for ambient temperature storage and distribution. Research studies suggest that under ultra shear conditions, unique microbiological, textural, sensory, and other benefits are possible. These benefits can lead to safer, higher quality, and more nutritious consumer-friendly "clean-label" (free of unwanted chemical additives) liquid foods and beverages. Consortium members receive a first right to non-exclusively license all new applications for commercial utilization in their own products. PBI has the right to license all new IP to non-members of the consortium worldwide. Known internationally for his research on high-pressure and other types of nonthermal processing, or safely processing food using significantly less heat, Dr. Bala leads a multidisciplinary team of microbiologists, chemists, and nutritionists, investigating innovative food technologies and partnering with industry to implement them commercially. He holds joint appointments in the CFAES departments of Food Science and Technology, and in Food, Agricultural and Biological Engineering. Other distinguished members of the CFAES research team include Ahmed Yousef, Professor of Food Microbiology; Rafael Jimenez-Flores, the J.T. "Stubby" Parker Endowed Chair in Dairy Foods; and Christopher Simons, Associate Professor of Sensory Science.お知らせ • Feb 09Pressure BioSciences, Inc. (OTCPK:PBIO) signed a letter of intent to acquire assets from Eco-friendly agrochemicals.Pressure BioSciences, Inc. (OTCPK:PBIO) signed a letter of intent to acquire assets from Eco-friendly agrochemicals on February 8, 2021. The asset purchase is subject to the negotiation and signing of definitive transaction documents.お知らせ • Jan 22Pressure BioSciences, Inc. Announces Collaboration with SinuSys CorporationPressure BioSciences, Inc. announced a collaboration with SinuSys Corporation. The primary goal of the collaboration is to evaluate the feasibility of PBI's innovative Ultra Shear Technology™ ("UST™") platform to improve the effectiveness of SinuSys Corp.'s lead product candidate Restora. If successful, SinuSys intends to license PBI's UST platform for use in Restora on its continued path to FDA approval in a Phase IIb clinical study later in 2021. SinuSys reports that chronic sinusitis affects more than 31 million people in the United States and that it is more prevalent than heart disease or asthma and has a greater impact on patients' quality of life than chronic back pain or congestive heart failure. The majority of patients with chronic sinusitis are treated with oral antibiotics and/or nasal steroids, which can increase the risk of antibiotic resistance and cause unwanted side effects such as nose bleeds, nasal ulcers, and nasal and oral infections. The most effective sinusitis treatment is Functional Endoscopic Sinus Surgery (FESS) with rapid balloon dilation at high pressures, which is known to cause significant patient discomfort and is conducted in a surgical suite under general anesthesia or IV sedation. Annually, it is estimated that $11 billion is spent in the U.S. alone on improving the health of patients with sinus conditions. SinuSys Corporation, a medical device company focused on developing new therapies to improve the sinus health of patients, is led by co-founder and CEO Thomas A. Schreck. Prior to SinuSys, Mr. Schreck was the founding Chairman and CEO of AcelRx, as well as the founding CEO and President, CFO, and Director of DURECT Corporation. He has also held various investment banking positions in the San Francisco Bay area and London and has raised over $300 million for medical device and biotechnology companies throughout his career. In the post-surgical nasal drug delivery markets, two companies that stand out at present are Intersect ENT and Lyra Therapeutics. Intersect is a medical technology company with existing products on the market, including mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. Lyra is a clinical-stage company developing drugs and new treatment options targeting ears, nose, and throat ("ENT") conditions.お知らせ • Oct 07Pressure BioSciences, Inc. Achieves Critical Milestone in Revolutionary Nanoemulsification Technology Development; Enters Production Era for Commercial System DevelopmentPressure BioSciences, Inc. announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("UST™")-based nanoemulsification system. Following achievement of this milestone, the Company has begun to build the initial "Alpha" unit of the commercial model. Once built, tested, and approved, the Company will immediately proceed to build an additional 15 ready-for-sale systems, thus enabling PBI to meet its goal of shipping the BaroShear K45 UST System in early (first quarter/second quarter) 2021. Based on the Company's patented UST platform, the BaroShear K45 is a unique breakthrough nanoemulsification system designed to resolve one of the most substantive problems facing manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products), and other products containing oil-based active ingredients that are at best poorly soluble in water. As with any oil-based product, it is difficult for the water-based biochemistry of humans and other animals to access and absorb the active ingredients hidden within oil drops. Poor water solubility leads to lower absorption and bioavailability of active ingredients, which makes it particularly difficult to design and deliver proper dosing of the desired compound. More recently, growing science around nanoemulsion development has shown that oil-based active ingredients manufactured into high quality nanoemulsions have delivered dramatically increased absorption and bioavailability, resulting in higher quality finished products for the consumer. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pressure BioSciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:PBIO - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20241-33-4-4N/A3/31/20242-37-5-5N/A12/31/20232-35-3-3N/A9/30/20232-30-3-3N/A6/30/20232-28-4-4N/A3/31/20232-20-4-4N/A12/31/20222-18-4-4N/A9/30/20221-17-4-4N/A6/30/20222-19-5-5N/A3/31/20222-20-5-4N/A12/31/20212-23-5-5N/A9/30/20212-23-5-5N/A6/30/20212-21-4-4N/A3/31/20212-20-5-5N/A12/31/20201-18-5-5N/A9/30/20201-17-5-5N/A6/30/20201-18-6-6N/A3/31/20202-17-6-6N/A12/31/20192-16-6-6N/A9/30/20192-17-7-7N/A6/30/20192-16-6-6N/A3/31/20192-25-6-6N/A12/31/20182-23-6-6N/A9/30/20182-21-5-4N/A6/30/20182-20-4-4N/A3/31/20182-7N/A-4N/A12/31/20172-11N/A-4N/A9/30/20172-5N/A-4N/A6/30/20172-4N/A-4N/A3/31/20172-3N/A-4N/A12/31/20162-3N/A-4N/A9/30/20162-10N/A-4N/A6/30/20162-10N/A-4N/A3/31/20162-10N/A-4N/A12/31/20152-7N/A-4N/A9/30/20152-5N/A-4N/A6/30/20152-5N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PBIOの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PBIOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PBIOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PBIOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PBIOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PBIOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:48終値2026/05/22 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pressure BioSciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Juan NobleTaglich Brothers, Inc.
お知らせ • Dec 23Pressure Biosciences Provides Revenue Guidance for Fourth Quarter 2022 and First Quarter 2023Pressure BioSciences provided revenue Guidance for fourth quarter 2022 and First quarter 2023. Company offered guidance that its Fourth Quarter 2022 revenue will exceed quarterly revenue for any quarter over the past four years, and may achieve the highest quarterly revenue ever for the Company. The Company further believes First Quarter 2023 revenue will greatly exceed Fourth Quarter 2022's expected strong results, and that revenues in each successive quarter will surpass the prior quarter's level. Management expects the Company to reach breakeven/profitability by the end of 2023.
お知らせ • May 18Pressure BioSciences, Inc. announced delayed 10-Q filingOn 05/17/2024, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Pressure BioSciences, Inc. announced delayed annual 10-K filingOn 04/01/2024, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 23Pressure BioSciences, Inc. (OTCPK:PBIO) completed the acquisition of CBH International LLC.Pressure BioSciences, Inc. (OTCPK:PBIO) entered into a definitive agreement to acquire CBH International LLC on January 11, 2024. Under the terms of the agreement, Uncle Bud's stockholders will be entitled to receive preferred stock of PBIO that is convertible into shares of PBIO common stock and no cash at the closing of the transaction. In addition, the parties agreed to an earnout for additional shares of PBIO common stock based on the achievement of revenue and net profit results in 2024. Such shares will be subject to standard restrictions on resale. Upon the closing of the transaction, the combined company intends to become a leading provider of topicals and other consumer products, leveraging PBIO’s UltraShear technology platform for nanoemulsified products that deliver industry-leading speed of action and bioavailability. All employees of CBH International became employees of Pressure BioSciences and CBH International became the Consumer Products Business Unit of Pressure BioSciences. The transaction has been unanimously approved by the Boards of Directors of both companies and is subject to customary closing conditions. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close by January 19, 2024.Pressure BioSciences, Inc. (OTCPK:PBIO) completed the acquisition of CBH International LLC on January 22, 2024.
お知らせ • Dec 13Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food SafetyPressure BioSciences, Inc. announced the publication of a pivotal scientific study in the critical field of food safety, featuring the Company's Ultra Shear TechnologyTM (UltraShearTM orUSTTM) platform. The recently published article, entitled "Synergistic Effects of Pressure, Temperature, Shear, and Their interactions on Clostridium sporogenes PA3679 Spore Inactivation During Ultra-Shear Processing" was featured in the peer-reviewed journal "Innovative Food Science and Emerging Technologies." This collaborative effort involved esteemed academic scientists from The Ohio State University ("Ohio State") College of Food, agricultural, and Environmental Sciences ("CFAES"), with co-authorship by PBIO's Senior Vice President of Engineering, Dr. Edmund Y. Ting. The publication underscores the efficacy of PBI's revolutionary USTTM platform in advancing food safety, preservation, stability, and enhancing consumer sensory experiences. The collaborative effort between The Ohio State University and PBIO has successfully developed conditions that leverage the positive effects of high-pressure homogenization, controlled exposure to elevated temperatures, and high hydrostatic pressure within the UltraShear equipment, resulting in a significant reduction of viable bacterial spores while maintaining high product quality compared to current food processing methods such as thermal inactivation. Key Highlights from the Publication: The article demonstrates the potential of UltraShear inactivation of foodborne bacterial spores by uniquely combining controlled temperature, pressure, and high fluid shear; The publication signals the future possibility of UltraShear processing of shelf-stable low-acid fluid products to maximize nutritional and sensory qualities for heat-sensitive products while significantly decreasing the potential of bacterial contamination, including spores; The authors validated the compatibility of conventional clean-in-place protocols with the UltraShear equipment.
お知らせ • Dec 02Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST AmbassadorPressure BioSciences, Inc. announced that VST has launched public availability of their first collaboration product, a Nano CBD Topical Spray with revolutionary fast performance enabled by PBIO's unique, patented UltraShear™ nanoemulsions platform technology. Marketed by VST, the product is named "Valor CBD" inspired by the courage of Nation's true heroes, the men and women who have selflessly served country. PBIO's UltraShear™ Technology (UltraShearTM or USTTM) platform allows oil-soluble active molecules (like CBD) to be prepared into nanoemulsions of vanishingly tiny oil droplets in water. The precisely controlled resulting nano-emulsion ensures breakthrough speed of absorption and unparalleled circulating availability of the active oil-soluble ingredients (CBD or other active molecules) to the water-based biochemistry of bodies (human or animals). "Quite simply, conventional oil and cream products have a low rate of absorption, so the products do not work quickly or effectively. Products made with UltraShear platform change that equation completely, producing nanoemulsions of CBD oil in water ("Nano CBD"), that deliver unprecedented speed of topical action, unparalleled bioavailability, and reliably dosed payload delivery," commented John B. Hollister, PBIO's Director of Marketing and Sales. Mr. Hollister added that PBIO is now capable of commercially processing Nano CBD in the Company's west coast partner's manufacturing facilities. This past summer, PBIO announced a five-year strategic partnership with VST, focused on benefiting the broad active duty and veteran's communities. Howard Zall, COO of VST, stated that VST had independently determined that PBIO's Ultra Shear Technology was the world's leading platform for creating the most highly effective nanoemulsions of CBD in either topical or oral spray formats.
お知らせ • Nov 17Pressure BioSciences, Inc. announced delayed 10-Q filingOn 11/15/2023, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Pressure BioSciences, Inc. announced delayed 10-Q filingOn 08/15/2023, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 18Pressure BioSciences, Inc. Announces UltraShear Nano-CBD Roll-Out Program Enters Rapid Expansion Phase of Distribution and PartneringPressure BioSciences, Inc. announced in an interview with renowned cannabis business authority Jeffrey Friedland that PBIO was now advancing into Phase 2 of commercialization of its revolutionarily-effective, UltraShear™-processed nanoemulsified CBD topical spray, transitioning from early, targeted sales and marketing efforts into rapid expansion plans for its nationwide and global distribution base. PBIO's President and CEO, Mr. Richard T. Schumacher explained in the interview: There has been significant noise in the CBD and broader cannabis markets from companies touting a nanoemulsion offering in the past few years, but none are able to match UltraShear's capability to deliver tightly controlled nano-droplet sizes in the sub-100 nm range, with rock-solid stability, easily and affordable scaled-up production efficiency, and elimination of the metal contamination resulting from the most commonly-used competitive technology. The company initially hand-picked a small, select group of retailers for its first round of efforts in the sale and distribution of the company’s Nano-CBD Topical Spray product, which allowed the company to explore and optimize factors like product formulation, CBD concentration targets, bottle and dispenser technology, product size and packaging configuration, pricing, and shipping logistics. This first phase of activity was extremely productive in answering those questions. The company now have a confidently-designed product and an accumulation of powerful UltraShear Nano-CBD Topical Spray user testimonials. Mr. Schumacher continued: Effective this week, the company enter PBIO's Phase 2 of the company's Nano-CBD commercialization strategy with rapidly expanding efforts to welcome and integrate many additional retailers and wholesalers across the USA, while the company introduce and establish it uniquely fast-acting and potent Nano-CBD topical spray to the broader U.S. and global markets. As the company had mentioned in recent news releases, independent research by a leading cannabis academic team has dramatically confirmed its UltraShear-processed Nano-CBD product to have uniquely differentiated performance over all existing known CBD products (compared to the gold standard of IV infusion), and the company anticipate the release of those results in a peer-reviewed scientific journal in the near future. Pressed by Mr. Friedman to discuss the expected impact of this announced Phase 2 upon PBIO's business results for the remainder of 2023 and beyond, Mr. Schumacher concluded: the company anticipate signing up over 20 retailers and wholesalers in the remainder of 2023, with an estimated incremental revenue impact of $2 million to $3 million over 2022 results. The company also plan to launch its UltraShear Nano-CBD OralSpray product this October 2023. Over the next 12 months, the company’s goal is to sign and launch at least 50 new UltraShear Nano-CBD retailers and wholesalers, and to achieve at least $10 million in incremental revenue impact in 2024.
お知らせ • Jun 28Pressure Biosciences, Inc. Announces Results from Third Round of Consumer Focus Group Testing of THC Nanoemulsion Oral SprayPressure BioSciences, Inc. announced results from a third round of consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks and under the tongue. The Nano-THC Oral Spray was prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products. An additional 25 consumers recently participated in this on-going focus group testing, bringing the total to over 60 participants to date. Once again, the respondents strongly affirmed key attributes that powerfully differentiate UltraShear processed Nano-THC Oral Spray from the participants previous edible THC experiences, with major emphasis on: Speedy onset of first effects (average well under ten minutes, with many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes for initial onset. Much faster progression to maximum effects (average well under 30 minutes, with many reports in 20 minutes or less) versus typical THC edibles requiring 60-120 minutes. Elimination of health issues associated with smoking or vaping. Efficiency improvements in dose payload delivery, with many reporting equal or better/greater THC experience from dosing at a fraction of user's normal dosing levels. Stable, all plant formulation is sterile packaged with no added preservatives. Multiple consumers applied a single spray to painful body areas and reported fast to instant transdermal pain relief. Multiple consumers with difficulty in falling asleep detailed how they quickly fell asleep and remained asleep through the night.
お知らせ • Jan 20Pressure Biosciences, Inc. Announces Results from Initial Consumer Focus Group Testing of A THC Nanoemulsion Oral Spray Prepared Using PBI's Revolutionary Ultra Shear TechnologyPressure BioSciences, Inc. announced results from initial consumer focus group testing of a THC Nanoemulsion Oral Spray prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™ or UST™) platform. Preparation of the THC Nanoemulsion Oral Spray was completed by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products in CA.
お知らせ • Dec 23Pressure Biosciences Provides Revenue Guidance for Fourth Quarter 2022 and First Quarter 2023Pressure BioSciences provided revenue Guidance for fourth quarter 2022 and First quarter 2023. Company offered guidance that its Fourth Quarter 2022 revenue will exceed quarterly revenue for any quarter over the past four years, and may achieve the highest quarterly revenue ever for the Company. The Company further believes First Quarter 2023 revenue will greatly exceed Fourth Quarter 2022's expected strong results, and that revenues in each successive quarter will surpass the prior quarter's level. Management expects the Company to reach breakeven/profitability by the end of 2023.
お知らせ • Dec 08+ 1 more updatePressure BioSciences, Inc., Annual General Meeting, Dec 29, 2022Pressure BioSciences, Inc., Annual General Meeting, Dec 29, 2022, at 11:00 US Eastern Standard Time.
お知らせ • Nov 16Pressure BioSciences, Inc. announced delayed 10-Q filingOn 11/15/2022, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 04Emergent Health Corp (OTCPK:EMGE) completed the acquisition of Pressure BioSciences, Inc. (OTCPK:PBIO).Emergent Health Corp (OTCPK:EMGE) executed a Letter of Intent to acquire Pressure BioSciences, Inc. (OTCPK:PBIO) on July 6, 2022. On July 19, 2022, Regen's Bankruptcy Motion to Dismiss was approved by the US Bankruptcy Court in New Jersey. The transaction is anticipated to close from mid-to-end July 2022. The transaction is expected to close on or about August 1, 2022. Emergent Health Corp (OTCPK:EMGE) completed the acquisition of Pressure BioSciences, Inc. (OTCPK:PBIO) on August 2, 2022. As per the terms of the transaction, acquisition was made for preferred stock of Emergent and other financial considerations. Jim Morrison, President and Chief Executive Officer of Regen has joined the Emergent Board of Directors.
お知らせ • Jul 07Emergent Health Corp (OTCPK:EMGE) executed a Letter of Intent to acquire Pressure BioSciences, Inc. (OTCPK:PBIO)Emergent Health Corp (OTCPK:EMGE) executed a Letter of Intent to acquire Pressure BioSciences, Inc. (OTCPK:PBIO) on July 6, 2022. The transaction is anticipated to close from mid-to-end July 2022.
お知らせ • May 18Pressure BioSciences, Inc. announced delayed 10-Q filingOn 05/17/2022, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Pressure BioSciences, Inc. announced delayed annual 10-K filingOn 04/01/2022, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 18Pressure BioSciences, Inc. announced delayed 10-Q filingOn 08/17/2021, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Pressure BioSciences, Inc. announced delayed annual 10-K filingOn 04/01/2021, Pressure BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 25Pressure BioSciences and The Ohio State University Announce Food Industry Consortium to Advance Commercialization of PBI's Ultra Shear TechnologyPressure BioSciences, Inc. announced it has entered into a wide-ranging agreement with the College of Food, Agricultural, and Environmental Sciences at The Ohio State University ("Ohio State"). Under the Agreement, bench-top and floor model test systems of PBI's patented Ultra Shear Technology™ platform for the high shear processing of liquids under controlled temperature and pressure conditions will be set up in the acclaimed Ohio State food pilot plant. To help introduce the potential of the UST platform for strategic innovation to global food companies, PBI and Ohio State have announced the formation of a food industry consortium (the "Consortium"), whose members will have access to the UST test systems in the pilot plant, as well as licensing rights to the UST platform. The Consortium is the result of research initially sponsored by the USDA NIFA for which Ohio State and PBI gratefully acknowledge their support. The primary goals of the Consortium are to develop and improve new commercial applications of UST; help develop the scientific support needed to address possible regulatory issues; and to experience first-hand UST product development and pre-commercialization efforts. The Consortium will be open to food companies worldwide. Consortium members will help direct the scientific efforts of Ohio State and PBI across a universe of prospective liquid food & beverage projects. Topics of interest will include spore inactivation and other pathogen and spoilage factor control; enhanced taste, smell, and other sensory qualities; and the formation of highly stable products suitable for ambient temperature storage and distribution. Research studies suggest that under ultra shear conditions, unique microbiological, textural, sensory, and other benefits are possible. These benefits can lead to safer, higher quality, and more nutritious consumer-friendly "clean-label" (free of unwanted chemical additives) liquid foods and beverages. Consortium members receive a first right to non-exclusively license all new applications for commercial utilization in their own products. PBI has the right to license all new IP to non-members of the consortium worldwide. Known internationally for his research on high-pressure and other types of nonthermal processing, or safely processing food using significantly less heat, Dr. Bala leads a multidisciplinary team of microbiologists, chemists, and nutritionists, investigating innovative food technologies and partnering with industry to implement them commercially. He holds joint appointments in the CFAES departments of Food Science and Technology, and in Food, Agricultural and Biological Engineering. Other distinguished members of the CFAES research team include Ahmed Yousef, Professor of Food Microbiology; Rafael Jimenez-Flores, the J.T. "Stubby" Parker Endowed Chair in Dairy Foods; and Christopher Simons, Associate Professor of Sensory Science.
お知らせ • Feb 09Pressure BioSciences, Inc. (OTCPK:PBIO) signed a letter of intent to acquire assets from Eco-friendly agrochemicals.Pressure BioSciences, Inc. (OTCPK:PBIO) signed a letter of intent to acquire assets from Eco-friendly agrochemicals on February 8, 2021. The asset purchase is subject to the negotiation and signing of definitive transaction documents.
お知らせ • Jan 22Pressure BioSciences, Inc. Announces Collaboration with SinuSys CorporationPressure BioSciences, Inc. announced a collaboration with SinuSys Corporation. The primary goal of the collaboration is to evaluate the feasibility of PBI's innovative Ultra Shear Technology™ ("UST™") platform to improve the effectiveness of SinuSys Corp.'s lead product candidate Restora. If successful, SinuSys intends to license PBI's UST platform for use in Restora on its continued path to FDA approval in a Phase IIb clinical study later in 2021. SinuSys reports that chronic sinusitis affects more than 31 million people in the United States and that it is more prevalent than heart disease or asthma and has a greater impact on patients' quality of life than chronic back pain or congestive heart failure. The majority of patients with chronic sinusitis are treated with oral antibiotics and/or nasal steroids, which can increase the risk of antibiotic resistance and cause unwanted side effects such as nose bleeds, nasal ulcers, and nasal and oral infections. The most effective sinusitis treatment is Functional Endoscopic Sinus Surgery (FESS) with rapid balloon dilation at high pressures, which is known to cause significant patient discomfort and is conducted in a surgical suite under general anesthesia or IV sedation. Annually, it is estimated that $11 billion is spent in the U.S. alone on improving the health of patients with sinus conditions. SinuSys Corporation, a medical device company focused on developing new therapies to improve the sinus health of patients, is led by co-founder and CEO Thomas A. Schreck. Prior to SinuSys, Mr. Schreck was the founding Chairman and CEO of AcelRx, as well as the founding CEO and President, CFO, and Director of DURECT Corporation. He has also held various investment banking positions in the San Francisco Bay area and London and has raised over $300 million for medical device and biotechnology companies throughout his career. In the post-surgical nasal drug delivery markets, two companies that stand out at present are Intersect ENT and Lyra Therapeutics. Intersect is a medical technology company with existing products on the market, including mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. Lyra is a clinical-stage company developing drugs and new treatment options targeting ears, nose, and throat ("ENT") conditions.
お知らせ • Oct 07Pressure BioSciences, Inc. Achieves Critical Milestone in Revolutionary Nanoemulsification Technology Development; Enters Production Era for Commercial System DevelopmentPressure BioSciences, Inc. announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("UST™")-based nanoemulsification system. Following achievement of this milestone, the Company has begun to build the initial "Alpha" unit of the commercial model. Once built, tested, and approved, the Company will immediately proceed to build an additional 15 ready-for-sale systems, thus enabling PBI to meet its goal of shipping the BaroShear K45 UST System in early (first quarter/second quarter) 2021. Based on the Company's patented UST platform, the BaroShear K45 is a unique breakthrough nanoemulsification system designed to resolve one of the most substantive problems facing manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products), and other products containing oil-based active ingredients that are at best poorly soluble in water. As with any oil-based product, it is difficult for the water-based biochemistry of humans and other animals to access and absorb the active ingredients hidden within oil drops. Poor water solubility leads to lower absorption and bioavailability of active ingredients, which makes it particularly difficult to design and deliver proper dosing of the desired compound. More recently, growing science around nanoemulsion development has shown that oil-based active ingredients manufactured into high quality nanoemulsions have delivered dramatically increased absorption and bioavailability, resulting in higher quality finished products for the consumer.